Guardant Health (GH) Partners With Manulife to Launch Shield Multi-Cancer Detection Test in Asia

Guardant Health Inc. (NASDAQ:GH) is one of the most promising stocks under $100 to buy. On March 16, Guardant Health announced the launch of its Shield multi-cancer detection/MCD test in several Asian markets through a first-of-its-kind partnership with Manulife. This methylation-based blood test is designed to detect ten common types of cancer (including lung, breast, colorectal, and liver) in individuals aged 45 or older who are at typical risk. Starting in April, eligible Manulife customers in Hong Ko ...